Short description:
Cancer Treatments
Drug notes:
Also additional Clin2 pediatric glioma, Clin1 solid tumors; Pimasertib Clin1 solid tumors
Long description:
Day One Biopharmaceuticals is developing therapies for patients of all ages with life-threatening diseases. The most common childhood brain cancer is pediatric low-grade glioma (pLGG), and it currently lacks effective cures. Through partnering with leading clinical oncologists, families and scientists, Day One is identifying, acquiring and developing cancer treatments. Day One’s lead product, DAY101 (tovorafenib), is in Phase 1/2 clinical trials for treatment against pLGG. DAY101 is an orally-taken, brain-penetrant pan-RAF inhibitor. Day One’s pipeline also includes pimasertib, a small molecule inhibitor of MEK-1/-2.
Jobs:
Senior Director, Regulatory Advertising and Promot... San Francisco, CA|20 days ago
Senior Director Development Operations Remote - Work From Home anywhere in US/ Remote|20 days ago
Director Corporate Development, Search and Evaluat... San Francisco, CA|61 days ago
CMC, GMP QA, Regulatory CMC & Supply Chain San Francisco, CA|100+ days ago
Commercial, Portfolio Planning, Market Access, Sal... San Francisco, CA|100+ days ago
Finance, Accounting, Corp Dev, Corp Comm, & IT San Francisco, CA|100+ days ago
Legal San Francisco, CA|100+ days ago
Advocacy, Clin Dev, Clin Pharm, Dx/Clin Biomarkers... San Francisco, CA|100+ days ago
HR, TA, People Ops, & Administration San Francisco, CA|100+ days ago
Biometrics, Clin Ops, GCP QA & Regulatory Science San Francisco, CA|100+ days ago
Patient Safety, Non-Clinical & Translational Resea... San Francisco, CA|100+ days ago